AAPL283.98+2.24 (+0.79%) ▲|ABBV252.87-1.44 (-0.57%) ▼|ABT92.35-0.36 (-0.39%) ▼|ACN123.06-1.68 (-1.35%) ▼|ADBE204.11-2.32 (-1.12%) ▼|AMAT719.79+25.15 (+3.62%) ▲|AMD549.63+10.14 (+1.88%) ▲|AMGN360.37-0.18 (-0.05%) ▼|AMT164.83-3.84 (-2.28%) ▼|AMZN239.40-0.74 (-0.31%) ▼|AVGO376.18+3.73 (+1.00%) ▲|AXP343.60+2.81 (+0.82%) ▲|BA216.23+1.56 (+0.73%) ▲|BAC57.18-0.70 (-1.20%) ▼|BKNG181.06-1.35 (-0.74%) ▼|BLK958.70+8.86 (+0.93%) ▲|BMY58.00-0.55 (-0.94%) ▼|BNY144.54+0.79 (+0.55%) ▲|BRK-B496.53+0.60 (+0.12%) ▲|C141.31-1.22 (-0.85%) ▼|CAT1,051.77+19.17 (+1.86%) ▲|CL91.64-0.74 (-0.80%) ▼|CMCSA24.82+0.60 (+2.48%) ▲|COF204.16+1.98 (+0.98%) ▲|COP103.92-0.28 (-0.27%) ▼|COST943.46-3.22 (-0.34%) ▼|CRM156.50-1.48 (-0.93%) ▼|CSCO118.07+0.37 (+0.31%) ▲|CVS102.99-0.59 (-0.57%) ▼|CVX167.91-0.56 (-0.33%) ▼|DE623.55-1.46 (-0.23%) ▼|DHR191.37-1.42 (-0.73%) ▼|DIS97.01-0.88 (-0.89%) ▼|DUK126.87-1.46 (-1.14%) ▼|EMR142.43-0.40 (-0.28%) ▼|FDX320.24-5.17 (-1.59%) ▼|GD349.21+1.14 (+0.33%) ▲|GE376.13+2.42 (+0.65%) ▲|GEV1,117.17+14.66 (+1.33%) ▲|GILD125.55-0.78 (-0.62%) ▼|GM77.01-0.33 (-0.43%) ▼|GOOG349.79-1.49 (-0.42%) ▼|GOOGL351.81-1.84 (-0.52%) ▼|GS1,016.28-3.93 (-0.39%) ▼|HD350.35-0.47 (-0.13%) ▼|HON227.26-0.54 (-0.24%) ▼|IBM275.70-2.30 (-0.83%) ▼|INTC134.85+3.13 (+2.38%) ▲|INTU264.76-1.65 (-0.62%) ▼|ISRG399.73-6.25 (-1.54%) ▼|JNJ256.53-1.99 (-0.77%) ▼|JPM328.55-0.85 (-0.26%) ▼|KO81.68-0.97 (-1.17%) ▼|LIN516.83+5.77 (+1.13%) ▲|LLY1,215.00-14.93 (-1.21%) ▼|LMT502.50+0.43 (+0.09%) ▲|LOW218.47-1.18 (-0.54%) ▼|LRCX433.07+22.16 (+5.39%) ▲|MA511.45+1.81 (+0.36%) ▲|MCD268.17+0.99 (+0.37%) ▲|MDLZ59.38-0.77 (-1.28%) ▼|MDT79.40-1.53 (-1.89%) ▼|META557.09-5.51 (-0.98%) ▼|MMM163.60+1.17 (+0.72%) ▲|MO73.47-0.58 (-0.78%) ▼|MRK128.38-1.01 (-0.78%) ▼|MS209.96-1.77 (-0.83%) ▼|MSFT372.00+3.43 (+0.93%) ▲|MU1,137.89-7.39 (-0.65%) ▼|NEE87.61-1.05 (-1.18%) ▼|NFLX73.43-0.35 (-0.47%) ▼|NKE41.16-0.32 (-0.77%) ▼|NOW98.42-1.56 (-1.56%) ▼|NVDA196.57+1.60 (+0.82%) ▲|ORCL148.27+0.51 (+0.35%) ▲|PEP138.38-0.30 (-0.22%) ▼|PFE24.11-0.26 (-1.08%) ▼|PG145.48-2.97 (-2.00%) ▼|PLTR116.19+0.49 (+0.42%) ▲|PM181.83-1.05 (-0.57%) ▼|QCOM187.09-1.63 (-0.86%) ▼|RTX189.04+1.71 (+0.91%) ▲|SBUX104.41+0.35 (+0.34%) ▲|SCHW93.24+2.69 (+2.97%) ▲|SO95.86-0.89 (-0.92%) ▼|SPG224.75-2.77 (-1.22%) ▼|T21.23-0.57 (-2.59%) ▼|TMO500.70-5.57 (-1.10%) ▼|TMUS169.11-4.87 (-2.80%) ▼|TSLA411.56-0.28 (-0.07%) ▼|TXN291.61+6.13 (+2.15%) ▲|UBER74.63-0.83 (-1.09%) ▼|UNH414.70-4.80 (-1.14%) ▼|UNP270.00-2.76 (-1.01%) ▼|UPS107.72-0.24 (-0.22%) ▼|USB60.67-0.59 (-0.96%) ▼|V341.34-0.35 (-0.10%) ▼|VZ43.06-1.01 (-2.30%) ▼|WFC83.26-0.24 (-0.29%) ▼|WMT113.92-0.68 (-0.59%) ▼|XOM135.63-0.41 (-0.30%) ▼|AAPL283.98+2.24 (+0.79%) ▲|ABBV252.87-1.44 (-0.57%) ▼|ABT92.35-0.36 (-0.39%) ▼|ACN123.06-1.68 (-1.35%) ▼|ADBE204.11-2.32 (-1.12%) ▼|AMAT719.79+25.15 (+3.62%) ▲|AMD549.63+10.14 (+1.88%) ▲|AMGN360.37-0.18 (-0.05%) ▼|AMT164.83-3.84 (-2.28%) ▼|AMZN239.40-0.74 (-0.31%) ▼|AVGO376.18+3.73 (+1.00%) ▲|AXP343.60+2.81 (+0.82%) ▲|BA216.23+1.56 (+0.73%) ▲|BAC57.18-0.70 (-1.20%) ▼|BKNG181.06-1.35 (-0.74%) ▼|BLK958.70+8.86 (+0.93%) ▲|BMY58.00-0.55 (-0.94%) ▼|BNY144.54+0.79 (+0.55%) ▲|BRK-B496.53+0.60 (+0.12%) ▲|C141.31-1.22 (-0.85%) ▼|CAT1,051.77+19.17 (+1.86%) ▲|CL91.64-0.74 (-0.80%) ▼|CMCSA24.82+0.60 (+2.48%) ▲|COF204.16+1.98 (+0.98%) ▲|COP103.92-0.28 (-0.27%) ▼|COST943.46-3.22 (-0.34%) ▼|CRM156.50-1.48 (-0.93%) ▼|CSCO118.07+0.37 (+0.31%) ▲|CVS102.99-0.59 (-0.57%) ▼|CVX167.91-0.56 (-0.33%) ▼|DE623.55-1.46 (-0.23%) ▼|DHR191.37-1.42 (-0.73%) ▼|DIS97.01-0.88 (-0.89%) ▼|DUK126.87-1.46 (-1.14%) ▼|EMR142.43-0.40 (-0.28%) ▼|FDX320.24-5.17 (-1.59%) ▼|GD349.21+1.14 (+0.33%) ▲|GE376.13+2.42 (+0.65%) ▲|GEV1,117.17+14.66 (+1.33%) ▲|GILD125.55-0.78 (-0.62%) ▼|GM77.01-0.33 (-0.43%) ▼|GOOG349.79-1.49 (-0.42%) ▼|GOOGL351.81-1.84 (-0.52%) ▼|GS1,016.28-3.93 (-0.39%) ▼|HD350.35-0.47 (-0.13%) ▼|HON227.26-0.54 (-0.24%) ▼|IBM275.70-2.30 (-0.83%) ▼|INTC134.85+3.13 (+2.38%) ▲|INTU264.76-1.65 (-0.62%) ▼|ISRG399.73-6.25 (-1.54%) ▼|JNJ256.53-1.99 (-0.77%) ▼|JPM328.55-0.85 (-0.26%) ▼|KO81.68-0.97 (-1.17%) ▼|LIN516.83+5.77 (+1.13%) ▲|LLY1,215.00-14.93 (-1.21%) ▼|LMT502.50+0.43 (+0.09%) ▲|LOW218.47-1.18 (-0.54%) ▼|LRCX433.07+22.16 (+5.39%) ▲|MA511.45+1.81 (+0.36%) ▲|MCD268.17+0.99 (+0.37%) ▲|MDLZ59.38-0.77 (-1.28%) ▼|MDT79.40-1.53 (-1.89%) ▼|META557.09-5.51 (-0.98%) ▼|MMM163.60+1.17 (+0.72%) ▲|MO73.47-0.58 (-0.78%) ▼|MRK128.38-1.01 (-0.78%) ▼|MS209.96-1.77 (-0.83%) ▼|MSFT372.00+3.43 (+0.93%) ▲|MU1,137.89-7.39 (-0.65%) ▼|NEE87.61-1.05 (-1.18%) ▼|NFLX73.43-0.35 (-0.47%) ▼|NKE41.16-0.32 (-0.77%) ▼|NOW98.42-1.56 (-1.56%) ▼|NVDA196.57+1.60 (+0.82%) ▲|ORCL148.27+0.51 (+0.35%) ▲|PEP138.38-0.30 (-0.22%) ▼|PFE24.11-0.26 (-1.08%) ▼|PG145.48-2.97 (-2.00%) ▼|PLTR116.19+0.49 (+0.42%) ▲|PM181.83-1.05 (-0.57%) ▼|QCOM187.09-1.63 (-0.86%) ▼|RTX189.04+1.71 (+0.91%) ▲|SBUX104.41+0.35 (+0.34%) ▲|SCHW93.24+2.69 (+2.97%) ▲|SO95.86-0.89 (-0.92%) ▼|SPG224.75-2.77 (-1.22%) ▼|T21.23-0.57 (-2.59%) ▼|TMO500.70-5.57 (-1.10%) ▼|TMUS169.11-4.87 (-2.80%) ▼|TSLA411.56-0.28 (-0.07%) ▼|TXN291.61+6.13 (+2.15%) ▲|UBER74.63-0.83 (-1.09%) ▼|UNH414.70-4.80 (-1.14%) ▼|UNP270.00-2.76 (-1.01%) ▼|UPS107.72-0.24 (-0.22%) ▼|USB60.67-0.59 (-0.96%) ▼|V341.34-0.35 (-0.10%) ▼|VZ43.06-1.01 (-2.30%) ▼|WFC83.26-0.24 (-0.29%) ▼|WMT113.92-0.68 (-0.59%) ▼|XOM135.63-0.41 (-0.30%) ▼|
23.7 C
New York
Tuesday, June 30, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

EMGS AND ANA SIGNS STRATEGIC MOU TO BOOST JAPAN – MALAYSIA HIGHER EDUCATION MOBILITY

PUTRAJAYA, Malaysia, June 16, 2025 /PRNewswire/ -- Education Malaysia Global Services (EMGS) and All Nippon Airways (ANA), Japan's largest airline group, have officially signed...

Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC

SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of...

Global Times: Cultural inheritance must touch the heart first

BEIJING, June 15, 2025 /PRNewswire/ -- Dunhuang, with its millennia-old heritage, is finding new life through the energy and creativity of young people. Over...

Tokyo Gas Wins CNCF End User Case Study Contest for Driving Cloud Native Agility with Kubernetes, Argo and Istio

Company to present digital platform modernization success at KubeCon + CloudNativeCon Japan 2025 TOKYO, June 15, 2025 /PRNewswire/ -- The Cloud Native Computing Foundation® (CNCF®), which...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  presented the subgroup analysis data from the Phase III COMPASSION-16...

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 15, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers